Maleki Behnam, Sadeghian Amir M, Ranjbar Mitra
School of Medicine, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran.
School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
BMC Infect Dis. 2025 Jan 31;25(1):144. doi: 10.1186/s12879-025-10530-4.
Vaccination against SARS-CoV-2 has been crucial in impeding virus spread and preventing fatal complications. Despite growing evidence of vaccine efficacy, data on its impact on hospitalized patients remain limited. We aimed to estimate the risk of mortality, ICU admission, and hospitalization length among hospitalized COVID-19 patients based on vaccination status.
In this single-center cross-sectional study, we included patients above 16 years old hospitalized due to COVID-19. Patients were categorized as unvaccinated, partially vaccinated (single dose), or fully vaccinated (at least one booster dose). We performed logistic and linear regression analyses, including both bivariable and multivariable models, to evaluate the association between vaccination status, demographic characteristics, and study outcomes.
Of 299 participants, 21.7%, 15.7%, and 62.5% were unvaccinated, partially vaccinated, and fully vaccinated, respectively. Full vaccination was associated with significantly reduced mortality risk (OR: 0.235, 95%CI: 0.103-0.538) and lower ICU admission rates (OR: 0.252, 95%CI: 0.131-0.484). Vaccinated patients had shorter hospital stays (fully vaccinated: 6.38 ± 1.65 days; unvaccinated: 9.22 ± 2.84 days, p < 0.001). Older age independently predicted higher mortality (OR: 1.062, 95%CI: 1.030-1.095), ICU admission (OR: 1.047, 95%CI: 1.027-1.068), and longer hospital stays (estimate: 0.027, 95%CI: 0.012-0.043). Multiple comorbidities were associated with higher mortality and longer hospitalization (OR: 1.794, 95%CI: 1.244-2.587; estimate: 0.395, 95%CI: 0.142-0.648).
Full vaccination against SARS-CoV-2 is associated with significantly improved clinical outcomes in hospitalized COVID-19 patients, including reduced mortality, lower ICU admission rates, and shorter hospital stays.
针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的疫苗接种对于阻碍病毒传播和预防致命并发症至关重要。尽管越来越多的证据表明疫苗有效,但关于其对住院患者影响的数据仍然有限。我们旨在根据疫苗接种状况评估住院的2019冠状病毒病(COVID-19)患者的死亡风险、重症监护病房(ICU)入住率和住院时长。
在这项单中心横断面研究中,我们纳入了因COVID-19住院的16岁以上患者。患者被分为未接种疫苗、部分接种(单剂)或完全接种(至少一剂加强针)。我们进行了逻辑回归和线性回归分析,包括双变量和多变量模型,以评估疫苗接种状况、人口统计学特征与研究结果之间的关联。
在299名参与者中,未接种疫苗、部分接种和完全接种的分别占21.7%、15.7%和62.5%。完全接种疫苗与显著降低的死亡风险(比值比:0.235,95%置信区间:0.103 - 0.538)和较低的ICU入住率(比值比:0.252,95%置信区间:0.131 - 0.484)相关。接种疫苗的患者住院时间较短(完全接种疫苗者:6.38±1.65天;未接种疫苗者:9.22±2.84天,p<0.001)。年龄较大独立预测更高的死亡率(比值比:1.062,95%置信区间:1.030 - 1.095)、ICU入住率(比值比:1.047,95%置信区间:1.027 - 1.068)和更长的住院时间(估计值:0.027,95%置信区间:0.012 - 0.043)。多种合并症与更高的死亡率和更长的住院时间相关(比值比:1.794,95%置信区间:1.244 - 2.587;估计值:0.395,95%置信区间:0.142 - 0.648)。
针对SARS-CoV-2的完全接种疫苗与住院的COVID-19患者显著改善的临床结局相关,包括降低死亡率、降低ICU入住率和缩短住院时间。